Gilead Sciences (GILD) PT Bumped Up at Nomura
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/29/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- Bloom Energy shares fall on Oracle project halt
- Exclusive-Activist Jana pushes Fiserv to accelerate cost cuts and tap Palantir
- Stocks fall as higher oil prices, Treasury yields weigh
Merck (MRK) Over-Hyped in Hep C, Says Wells Fargo (GILD) (ABBV)
April 10, 2014 9:23 AM EDTWells Fargo analyst Brian Abrahams said Merck (NYSE: MRK) may be over-hyped as a hepC competitor to Gilead Sciences (NASDAQ: GILD).
"We are attending the EASL conference in London UK, where Merck has just pressreleased additional data from... More
